Literature DB >> 31925544

The differential activation of metabolic pathways in leukemic cells depending on their genotype and micro-environmental stress.

Caroline Lo Presti1,2, Florence Fauvelle3,4, Julie Mondet5,6, Pascal Mossuz7,5.   

Abstract

INTRODUCTION: Acute myeloid leukemia (AML) is characterized by a set of malignant proliferations leading to an accumulation of blasts in the bone marrow and blood. The prognosis is pejorative due to the molecular complexity and pathways implicated in leukemogenesis.
OBJECTIVES: Our research was focused on comparing the metabolic profiles of leukemic cells in basal culture and deprivation conditions to investigate their behaviors under metabolic stress.
METHODS: We performed untargeted metabolomics using 1H HRMAS-NMR. Five human leukemic cell lines-KG1, K562, HEL, HL60 and OCIAML3-were studied in the basal and nutrient deprivation states. A multivariate analysis of the metabolic profile was performed to find over- or under- expressed metabolites in the different cell lines, depending on the experimental conditions.
RESULTS: In the basal state, each leukemic cell line exhibited a specific metabolic signature related to the diversity of AML subtypes represented and their phenotypes. When cultured in a serum-free medium, they showed quick metabolic adaptation and continued to proliferate and survive despite the lack of nutrients. Low apoptosis was observed. Increased phosphocholine and glutathione was a common feature of all the observed cell lines, with the maximum increase in these metabolites at 24 h of culture, suggesting the involvement of lipid metabolism and oxidative stress regulators in the survival mechanism developed by the leukemic cells.
CONCLUSIONS: Our study provides new insights into the metabolic mechanisms in leukemogenesis and suggests a hierarchy of metabolic pathways activated within leukemic cells, some dependent on their genotypes and others conserved among the subtypes but commonly induced under micro-environmental stress.

Entities:  

Keywords:  Acute myeloid leukemia; HRMAS-NMR; Metabolic pathways; Metabolomics

Year:  2020        PMID: 31925544     DOI: 10.1007/s11306-020-1633-z

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  38 in total

Review 1.  Cell metabolomics.

Authors:  Aihua Zhang; Hui Sun; Hongying Xu; Shi Qiu; Xijun Wang
Journal:  OMICS       Date:  2013-08-29

2.  Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival.

Authors:  Julie Mondet; Caroline Lo Presti; Catherine Garrel; Kristina Skaare; Clara Mariette; Sylvain Carras; Sophie Park; Martin Carré; Claude-Eric Bulabois; Lysiane Molina; Rémy Gressin; Anne Thiebaut; Stéphane Courby; Nuria Socoro-Yuste; Patrice Faure; Anne Mc Leer-Florin; Jean-Yves Cahn; Pascal Mossuz
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

3.  Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells.

Authors:  June Li; Daniel P Sejas; Reena Rani; Tara Koretsky; Grover C Bagby; Qishen Pang
Journal:  J Biol Chem       Date:  2006-04-11       Impact factor: 5.157

4.  FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Authors:  Min Ye; Weiqin Lu; Xiaojie Wang; Cong Wang; James L Abbruzzese; Guang Liang; Xiaokun Li; Yongde Luo
Journal:  Endocrinology       Date:  2016-10-03       Impact factor: 4.736

5.  Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.

Authors:  Malihe Eskandarpour; Fei Huang; Karen A Reeves; Edwin Clark; Johan Hansson
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

6.  Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.

Authors:  Brian J Dewar; Kayvan Keshari; Rex Jeffries; Petras Dzeja; Lee M Graves; Jeffrey M Macdonald
Journal:  Metabolomics       Date:  2010-03-23       Impact factor: 4.290

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.

Authors:  Haymanti Bhanot; Mamatha M Reddy; Atsushi Nonami; Ellen L Weisberg; Dennis Bonal; Paul T Kirschmeier; Sabrina Salgia; Klaus Podar; Ilene Galinsky; Tirumala K Chowdary; Donna Neuberg; Giovanni Tonon; Richard M Stone; John Asara; James D Griffin; Martin Sattler
Journal:  Leukemia       Date:  2015-02-23       Impact factor: 11.528

Review 9.  Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.

Authors:  Mei Han; Lina Jia; Wencai Lv; Lihui Wang; Wei Cui
Journal:  Front Oncol       Date:  2019-03-29       Impact factor: 6.244

10.  Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines.

Authors:  Stefano Tiziani; Alessia Lodi; Farhat L Khanim; Mark R Viant; Christopher M Bunce; Ulrich L Günther
Journal:  PLoS One       Date:  2009-01-22       Impact factor: 3.240

View more
  4 in total

1.  The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker.

Authors:  Caroline Lo Presti; Florence Fauvelle; Marie-Christine Jacob; Julie Mondet; Pascal Mossuz
Journal:  Blood Adv       Date:  2021-01-12

2.  The Metabolic Signature of AML Cells Treated With Homoharringtonine.

Authors:  Yulong Zhang; Na Li; Zhiguang Chang; Huabin Wang; Hanzhong Pei; Dengyang Zhang; Qi Zhang; Junbin Huang; Yao Guo; Yuming Zhao; Yihang Pan; Chun Chen; Yun Chen
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

Review 3.  2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.

Authors:  Vittoria Raimondi; Giulia Ciotti; Michele Gottardi; Francesco Ciccarese
Journal:  Biomedicines       Date:  2022-06-09

4.  Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways.

Authors:  J Vial; P Huchedé; S Fagault; F Basset; M Rossi; J Geoffray; H Soldati; J Bisaccia; M H Elsensohn; M Creveaux; D Neves; J Y Blay; F Fauvelle; F Bouquet; N Streichenberger; N Corradini; C Bergeron; D Maucort-Boulch; P Castets; M Carré; K Weber; M Castets
Journal:  Cell Death Discov       Date:  2020-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.